MOTS vs. OSAP, AFIB, SINT, NMRD, BJDX, ACORQ, SXTC, PTEIQ, SIENQ, and APVO
Should you be buying Motus GI stock or one of its competitors? The main competitors of Motus GI include ProSomnus (OSAP), Acutus Medical (AFIB), Sintx Technologies (SINT), Nemaura Medical (NMRD), Bluejay Diagnostics (BJDX), Acorda Therapeutics (ACORQ), China SXT Pharmaceuticals (SXTC), PolarityTE (PTEIQ), Sientra (SIENQ), and Aptevo Therapeutics (APVO). These companies are all part of the "medical" sector.
ProSomnus (NASDAQ:OSAP) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
Motus GI has a consensus target price of $28.88, indicating a potential upside of 27,243.75%. Given ProSomnus' higher probable upside, analysts plainly believe Motus GI is more favorable than ProSomnus.
Motus GI received 163 more outperform votes than ProSomnus when rated by MarketBeat users.
ProSomnus has a net margin of -87.14% compared to ProSomnus' net margin of -3,239.75%. Motus GI's return on equity of 0.00% beat ProSomnus' return on equity.
In the previous week, Motus GI had 3 more articles in the media than ProSomnus. MarketBeat recorded 5 mentions for Motus GI and 2 mentions for ProSomnus. ProSomnus' average media sentiment score of 0.77 beat Motus GI's score of 0.00 indicating that Motus GI is being referred to more favorably in the news media.
Motus GI has lower revenue, but higher earnings than ProSomnus. ProSomnus is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.
70.0% of ProSomnus shares are held by institutional investors. Comparatively, 20.1% of Motus GI shares are held by institutional investors. 7.7% of ProSomnus shares are held by insiders. Comparatively, 1.6% of Motus GI shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ProSomnus has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.
Summary
Motus GI beats ProSomnus on 9 of the 16 factors compared between the two stocks.
Get Motus GI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Motus GI Competitors List
Related Companies and Tools
